• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value . | May 8, 2023
FOR46, an ADC targeting CD46, is in Phase 1 development with potential applications in mCRPC and other CD46-expressing cancersCollaboration expands FibroGen’s clinical pipeline with potential. | May 8, 2023
FibroGen (FGEN) Enters into Exclusive License for FOR46 with Fortis Therapeutics streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Operator: Thank you for standing by, and welcome to FibroGen s Fourth Quarter and Full Year 2022 Financial Results Earnings Call. . I would now like to hand the call over to your host, Mike Tung.
FibroGen, Inc. (NASDAQ:NASDAQ:FGEN) Q3 2022 Earnings Conference Call November 07, 2022, 17:00 ET Company Participants Michael Tung - IR Executive Enrique Conterno - CEO & Director Juan.